Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deferred Tax Liability: 2021-2024

  • Prime Medicine's Non-Current Deferred Tax Liability rose 74.03% to $134,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $134,000, marking a year-over-year increase of 74.03%. This contributed to the annual value of $8.7 million for FY2022, which is 46.57% up from last year.
  • Latest data reveals that Prime Medicine reported Non-Current Deferred Tax Liability of $134,000 as of Q1 2024, which was up 24.07% from $108,000 recorded in Q2 2023.
  • Prime Medicine's Non-Current Deferred Tax Liability's 5-year high stood at $8.7 million during Q4 2022, with a 5-year trough of $77,000 in Q1 2023.
  • Its 3-year average for Non-Current Deferred Tax Liability is $1.9 million, with a median of $134,000 in 2024.
  • Data for Prime Medicine's Non-Current Deferred Tax Liability shows a peak YoY soared of 74.03% (in 2024) over the last 5 years.
  • Prime Medicine's Non-Current Deferred Tax Liability (Quarterly) stood at $6.0 million in 2021, then skyrocketed by 46.57% to $8.7 million in 2022, then reached $108,000 in 2023, then soared by 74.03% to $134,000 in 2024.
  • Its last three reported values are $134,000 in Q1 2024, $108,000 for Q2 2023, and $77,000 during Q1 2023.